Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures

Status:
Completed

Trial end date:
2007-01-01

Target enrollment:

Participant gender:

This trial will evaluate the efficacy and safety of ucb 44212 as add on therapy in subjects with focal epilepsy.

Phase 2

UCB Pharma